Telix Pharmaceuticals Limited (TLX)

Amid rising inflation concerns, this article highlights three ASX stocks – Telix Pharmaceuticals (TLX), Lynas Rare Earths (LYC), and WiseTech Global (WTC) – that are identified as trading below their discounted cash flow values. Each company has unique cash flow potential from their operations and pipelines, offset by specific risks such as funding, regulatory issues, or execution challenges. The article suggests these mispriced opportunities may appeal to value-driven investors looking for dependable cash flows.

Telix Pharmaceuticals (TLX) stock climbed after reporting a strong first-half, with revenue up 22% and EBITDA surging 146%. The growth was driven by its precision medicine business and demand for imaging products, pushing the stock towards its 52-week high. Upcoming regulatory decisions for several pipeline products are anticipated to be key catalysts for future performance.

Telix Pharmaceuticals has seen its shares cool down recently, despite a strong first half of 2026 where it moved from a loss to a profit of US$38.33 million on US$477.35 million in revenue. The company's bull case hinges on its Precision Medicine cash engine funding a diversified radiopharmaceutical platform, with several late-stage therapies advancing. However, bears point to execution risks, including regulatory delays and slower international rollouts, which could impact the profitability of its cash engine before new therapies contribute significantly.

Telix Pharmaceuticals reported significant progress in its radiopharmaceutical imaging and therapeutic pipeline during the first half of 2026, achieving a 22% year-on-year revenue increase to $477 million. The company invested $124 million in R&D, focusing on late-stage therapeutics and precision medicine, particularly advancing treatments for prostate, brain, and kidney cancers. Telix also expanded its manufacturing infrastructure and formed a strategic collaboration with Regeneron to develop next-generation radiopharmaceutical therapies.

Telix Pharmaceuticals reported H1 2026 revenue of $477 million, a 22% year-on-year increase, driven by its radiopharmaceutical imaging and therapeutic pipeline. The company is advancing pivotal-stage programs for prostate, brain, and kidney cancers, investing $124 million in R&D, and expanding its manufacturing capabilities. Key developments include progress in prostate cancer imaging and therapeutic candidates, a strategic collaboration with Regeneron, and nearing completion of patient enrollment in several Phase III studies.